TITLE

Effects of Paroxetine and Sertraline on Low-Density Lipoprotein Cholesterol

AUTHOR(S)
Feifei Wei; Crain, A. Lauren; Whitebird, Robin R.; Godlevsky, Olga V.; O'Connor, Patrick J.
PUB. DATE
October 2009
SOURCE
CNS Drugs;2009, Vol. 23 Issue 10, p857
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Antidepressant use in US adults increased 3-fold from 2.5% in 1988-94 to 8.1% in 1999-2002, based on National Health and Nutrition Examination Surveys. As the use of antidepressants increases, a comprehensive understanding of the potential health risks that may be associated with their use becomes increasingly important. Objective: This study evaluated the effects of paroxetine and sertraline on low-density lipoprotein cholesterol (LDL-C). Study Design: An observational cohort study (1997-2004) of adults who had taken paroxetine or sertraline for at least 60 continuous days and had ≥2 LDL-C values measured during the study period, one while taking and one while not taking paroxetine or sertraline. A total of 13 634 LDL-C values clustered within 2682 patients were studied. Methods: We conducted mixed model regression analyses to quantify the relationship between antidepressant use and LDL-C values. Results: The number of days taking paroxetine (β = 0.0045; 95% CI 0.0018, 0.0073) and sertraline (β = 0.0074; 95% CI 0.0054, 0.0093) prior to the LDL-C test were related to higher LDL-C values, after accounting for age, sex, year LDL-C was tested, co-morbidity, depression and lipid medication. The number of days that had passed since exposure to paroxetine (β=-0.0013; 95% CI -0.0020, -0.00061) or sertraline (β=-0.00093; 95% CI -0.016, -0.00022) were related to lower LDL-C values. The significant interaction between exposure to an antidepressant and taking a lipid medication demonstrates that the increase in LDL-C values associated with antidepressant use is ameliorated among patients who were taking a lipid medication when LDL-C was measured. Conclusion: Our study showed that long-term use of paroxetine or sertraline may have a measurable adverse impact on cardiovascular risk in adults. Clinical strategies should be used to address cardiovascular risk while maintaining effective treatment of major depression. In light of these findings, attention to LDL-C values should accompany antidepressant use.
ACCESSION #
44255255

 

Related Articles

  • Gabapentin and nortriptyline combined was better than either drug alone for relief of neuropathic pain. Hughes, James // ACP Journal Club;3/16/2010, Vol. 152 Issue 3, p5 

    The article focuses on a medical research related to effectiveness of combined gabapentin and nortriptyline in comparison to alone drug for neuropathic pain. In a clinical trial around 56 patients with neuropathy is being observed and treated with combined drugs. It concluded that gabapentin and...

  • Karo Bio Eyes 2011 Start for Eprotirome Pivotal Program. Sheridan, Cormac // BioWorld International;9/1/2010, Vol. 15 Issue 34, p1 

    The article offers information on final preparation done by Karo Bio AB for a Phase III trial of its drug candidate eprotirome for the treatment of heterozygous familial hypercholesterolemia (HeFH). The company is aiming to recruit 625 patients with HeFH, a genetic condition characterized by...

  • Encouraging Research Shows New Cholesterol Busters Safe, Effective.  // Heart Advisor;Jul2014, Vol. 17 Issue 7, p1 

    The article focuses on the statin alternative experimental medicine PCSK9 inhibitors design to manage low-density lipoprotein (LDL) cholesterol. Topics discussed include the experiment in Utilizing an Anti-PCSK9 antibody in Statin Intolerant Subjects-2 (GAUSS-2) focuses on the evolucumab,an...

  • HDL-cholesterol and CV outcomes: The debate continues... Vora, Jiten // Diabetes Digest;2012, Vol. 11 Issue 3, p174 

    The author comments on cardiovascular benefits of lipidlowering therapy that are recognised as being related to lowering low-density lipoprotein cholesterol (LDL-C) although studies suggested that raising high-density lipoprotein cholesterol (HDL-C) is associated with a reduction in...

  • Colesevelam (WelChol) for Reduction of LDL Cholesterol. Radosh, Lee // American Family Physician;7/15/2005, Vol. 72 Issue 2, p321 

    Evaluates the drug colesevelam for the reduction of elevated low-density lipoprotein cholesterol levels in patients with primary hypercholesterolemia. Safety; Effectiveness; Price.

  • Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial. Locatelli, Francesco; Dimkovic, Nada; Spasovski, Goce // Nephrology Dialysis Transplantation;Jul2013, Vol. 28 Issue 7, p1874 

    Background Colestilan is a non-absorbed, non-calcium-based, phosphate binder. It also binds bile acids and reduces serum levels of low-density lipoprotein cholesterol (LDL-C). This study evaluated the efficacy of a range of fixed doses of colestilan compared with placebo for the control of serum...

  • Efficacy is similar among second-generation antidepressants.  // Formulary;Dec2008, Vol. 43 Issue 12, p463 

    The article presents several studies on the efficacy of the second-generation antidepressants. In seven studies, mirtazapine was found to have a faster onset of action compared with citalopram, fiuoxetine, paroxetine, and sertraline after one to two weeks of treatment. After four weeks of...

  • Model-Based Approach and Signal Detection Theory to Evaluate the Performance of Recruitment Centers in Clinical Trials With Antidepressant Drugs. Merlo-Pich, E.; Gomeni, R. // Clinical Pharmacology & Therapeutics;Sep2008, Vol. 84 Issue 3, p378 

    The objective of this study was to characterize the performance of each recruitment center in multicenter clinical trials and to provide criteria to discriminate between informative and noninformative centers using the signal detection approach. Data were derived from the GlaxoSmithKline...

  • THE EFFICACY AND TOLERABILITY OF ESCITALOPRAM DURING 6 MONTHS OF OUTPATIENT'S TREATMENT. Hruby, Radovan; Ondrejka, Igor; Nosalova, Gabriela; Hruba, Sabina; Kerna, Jr., Valeria // Biomedical Papers of the Medical Faculty of Palacky University i;2007, Vol. 151, p33 

    An abstract of the medical research "THE EFFICACY AND TOLERABILITY OF ESCITALOPRAM DURING 6 MONTHS OF OUTPATIENT'S TREATMENT," by Radovan Hruby, Igor Ondrejka, Gabriela Nosalova, Sabina Hruba and Valeria Kerna Jr. is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics